Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
about
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individualsThe 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansRelationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureIndividualization of antiretroviral therapy--pharmacogenomic aspectCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsImpact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling.Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Zidovudine as modern day salvage therapy for HIV infection.Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionRecent developments in HIV-related kidney disease.Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialChanges in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The NetherlandsRenal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Management of HIV infection in treatment-naive patients: a review of the most current recommendations.Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia.Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database.An update on the use of Atripla in the treatment of HIV in the United States.Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational SettingsNew option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Survival benefits of antiretroviral therapy in Brazil: a model-based analysis."One pill, once daily": what clinicians need to know about Atriplatrade mark.Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens
P2860
Q24234651-93996C89-8D43-428A-BFB9-DE73028B653AQ26781379-F413094E-C723-4E9E-8654-3086B3774DB6Q27003431-CC318CCB-0E3E-4D80-A173-0A017D691549Q28070574-721EFCF4-5EF9-4BF7-A0D4-E692DCA7B177Q28482138-D42EE0F1-3F27-44F7-95FD-A559E7979BEAQ28543075-4C8A51F9-A16B-4BA2-8E8F-F7EC57367946Q28547109-EC68AA6F-90FC-4C11-BCA1-65A085CA93AFQ31028855-06A8C4C9-1C3B-4BAF-B830-A2AEBD7ACD9EQ33775397-E5375A0D-7E0B-4788-AC1B-836DE7ABCD9CQ33940190-7AF83E57-7A35-4CB9-B70A-E52C9879F991Q33982131-695875C7-FB97-44B2-A172-C332EC842029Q34060396-A42359D0-D74E-466A-9396-E1608DB99C2DQ34436988-4B3C59C5-1A16-44B5-B342-9CABE861254CQ34475217-6034F204-21DD-481D-88B5-AAD4243BFCF4Q34478840-FFCD799A-8ED8-4FD7-9274-2330BC8CEE77Q34481359-DC5A3E41-3F4E-4BBD-A2D5-6E7EEE0169D4Q34572458-68F96AA2-AD4C-401A-AABD-6723007E05A8Q34768650-82FDBF5E-3147-415B-BD99-98D33F53D401Q34952127-68247645-DFE0-477E-9BA5-4084A48D8EB0Q35010207-9BEF84AE-FDBF-4AEE-962D-96D59079F215Q35170350-C8987329-56AA-4A07-8FF7-A235681261A4Q35186842-5A7A08CD-0074-41A3-9A0B-94474D5725D9Q35188723-079F0959-F596-4A02-A014-3D32B947CB22Q35217508-0FD7BD10-07AC-4078-A17E-EACA4DFB6B0EQ35534418-7BF40D17-4489-48F2-A426-16321B3DECDDQ35557269-86873C20-85EF-4079-A619-01CB5DF0E520Q35602604-43C2C778-DEA1-4606-BA5A-24856C824081Q35838930-ABF384BE-FA56-4521-8D2B-8CC7FAF0DBE8Q35881469-2B55894E-039C-4388-B9D4-2B7020C5AD49Q35939695-BFDE6005-0054-4900-98C8-9AA390E4C6B2Q36097686-1B54C76D-0227-4EF7-8B12-7903395145A8Q36237157-76974B4B-9E9B-4C3D-9DF6-62390A56FD52Q36284159-C338B503-BEE7-4F1A-A256-163E5FEDD582Q36617684-AB210B9C-08CF-4F45-81B2-1B22A4360142Q36723349-1436BEF2-0E99-40CF-90FE-CFC560D22A48Q36747289-3004C5FE-9709-4E66-9492-A460A7B7EDD3Q36823570-B270C580-E49F-47EE-886C-F28F6633EDE7Q36994977-73768B1D-A849-45B0-BD0C-38BBF547003AQ37184431-C3F9CC0D-0AEE-4A95-9D6F-1FBC1A344AFFQ37263602-3DD63BE0-A1BA-49E6-99D7-0F05028FBC07
P2860
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@en
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@nl
type
label
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@en
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@nl
prefLabel
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@en
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@nl
P2093
P1476
Tenofovir disoproxil fumarate, ...... e patients: 144-week analysis.
@en
P2093
Andrew K Cheng
Anton L Pozniak
Brian Gazzard
Charles B Holmes
Damian McColl
Edwin Dejesus
Jeffrey Enejosa
Joel E Gallant
John J Toole
Rafael E Campo
P356
10.1097/QAI.0B013E31815ACAB8
P407
P577
2008-01-01T00:00:00Z